Core Insights - The weight-loss drug market is rapidly growing, with investment opportunities in established companies like Eli Lilly and Novo Nordisk, as well as smaller biotech firms like Viking Therapeutics [1][2] Company Overview - Viking Therapeutics is focusing on developing VK2735, a GLP-1 medicine currently in phase 3 clinical trials, which increases the likelihood of approval compared to candidates in earlier stages [5][10] - The company is exploring both subcutaneous and oral formulations of VK2735, aiming to address the challenge of maintaining weight loss after treatment [7][8] Market Potential - As of mid-2025, there are 277 obesity-drug candidates in development, but most are unlikely to receive approval, highlighting the competitive nature of the market [4] - Viking's strong mid-stage results for VK2735 position it favorably within this competitive landscape, potentially leading to significant financial success and stock market returns over the next decade [8] Investment Considerations - Investing in Viking Therapeutics is considered riskier but may offer higher upside potential, with a suggested investment of $5,000 for those with above-average risk tolerance [2][10] - The success of VK2735 in phase 3 trials is critical for the company's future market impact and stock performance [10]

Core Insights - Eli Lilly has built a pre-launch inventory of its experimental oral weight-loss drug, orforglipron, valued at $1.5 billion ahead of an expected FDA decision in April [1] - This inventory has increased significantly from nearly $550 million reported last year, indicating strong preparation for a potential launch [1] - The company aims to have sufficient supply to launch the drug in multiple countries simultaneously if it receives U.S. approval [1] Company Developments - Eli Lilly's orforglipron has received a fast-track review voucher from the FDA, potentially reducing the review time to one to two months compared to the typical 10 to 12 months for new medicines [1] - The competitive landscape includes Danish rival Novo Nordisk, which recently launched its own weight-loss pill in the U.S., achieving over 26,000 prescriptions in the second week post-launch [1] Financial Implications - The pre-launch inventory is a strategic asset that reflects Eli Lilly's confidence in the drug's approval and market potential [1] - Such inventories are commonly included in financial statements to demonstrate the readiness of drug products prior to regulatory approval [1]

Nam, could you just tell us about the shift that's taking place right now in the global market for for weight loss drugs. >> So, I mean, we're we're going really from a few years where Novon Nordisk couldn't make enough semiglutide to supply the market um in the US, let alone in the rest of the world. um to a time when um in a growing number of countries there will be a lot of generic competitors on the market and people will suddenly have access that they never had before to super powerful obesity medicine ...

Eli Lilly & Co. provided an upbeat sales forecast for the year Wednesday as strong demand for its weight loss drug cemented its position at the top of the obesity market.The guidance was a sharp contrast to rival Novo Nordisk A/S, which warned investors Tuesday that its sales could drop as much as 13 per cent this year on intensifying price competition in the weight loss market. Lilly, on the other hand, expects its sales to grow as much as 27 per cent this year.Lilly’s shares rose 8.3 per cent at 9:32 a.m. ...

Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, as it expects strong demand for its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro, to offset pricing pressures in the U.S., its largest market. ...

Restaurant chains are pumping protein into everything from pizza crust to coffee, while stepping up marketing to users of weight-loss drugs and fitness buffs https://t.co/XIJcBbPmLA ...

Popular weight-loss drugs are meant to be lifelong medications treating a disease, not lifestyle fixes. https://t.co/POIwSSrK05 ...

Group 1: Cost Savings for Airlines - Airlines could save approximately $580 million annually due to reduced passenger weight from weight-loss drugs, leading to lower fuel costs [1] - The top four U.S. airlines—American Airlines, Delta Air Lines, Southwest Airlines, and United Airlines—are expected to benefit from these savings [1] Group 2: Impact of Weight-Loss Drugs - The popularity of weight-loss drugs like Ozempic and Wegovy is rising in the U.S., contributing to the potential weight reduction among travelers [5] - Novo Nordisk is developing an oral version of Wegovy, which has recently been approved and launched, potentially increasing accessibility for patients who prefer not to use injections [8] Group 3: Market Reactions - The stock performance of major airlines shows mixed results, with Southwest Airlines slightly up by 0.05%, while United Airlines, Delta Air Lines, and American Airlines experienced declines of 2.18%, 1.28%, and 2.16% respectively [6]

Key Points Eli Lilly's weight-loss drugs are experiencing rapid growth. It still has a long way to go to help curb obesity rates around the globe. The stock trades at a premium earnings multiple, but this is expected to decrease in the coming years. 10 stocks we like better than Eli Lilly › Shares of Eli Lilly (NYSE: LLY) jumped 39.2% in 2025, according to data from S&P Global Market Intelligence. The drugmaker is seeing soaring sales due to its blockbuster weight loss products called Zepbound an ...

Market Trends - The weight-loss drug market is expected to go truly global in 2026 due to the availability of cheap generic versions and new treatments in pill form [1]